Tandem Diabetes Care Announces First Quarter 2026 Financial Results

About this update from Tandem Diabetes Care, Inc.

SAN DIEGO, May 07, 2026--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2026 and reaffirmed financial guidance for the year ending December 31, 2026. First Quarter 2026 Financial and Strategic Highlights "In the first quarter, we delivered on our financial plan while initiating key operational steps to advance our strategic priorities," said John Sheridan, president and chief executive officer. "Our 2026 goals are firmly in focus, and we are committed to providing innovative, best-in-class diabetes technology to our customers in more efficient and cost-effective ways, while strengthening our global business model and building long-term value for shareholders." First Quarter 2026 Financial Results Compared to First Quarter 2025 (1) Constant currency sales growth is a non-GAAP measure that represents the change in sales between current and prior year periods using the exchange rate in effect during the applicable prior year period. The Company presents constant currency growth because management believes it provides meaningful information regarding the Company’s results on a consistent and comparable basis. The Company uses this non-GAAP measure to evaluate operating results. A reconciliation of constant currency to GAAP sales can be found in Table C "Sales by Geography and Non-GAAP Reconciliation of Constant Currency Sales Growth" attached to this press release. Also see "Non-GAAP Financial Measures" below for additional information. (2) A reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures and additional information can be found in Table D "Reconciliation of GAAP versus Non-GAAP Financial Results" attached to this press release. Also see "Non-GAAP Financial Measures" below for additional information. See tables for additional financial information. 2026 Financial Guidance For the year ending December 31, 2026, the Company is reaffirming its financial guidance as follows: For a comprehensive overview of the Company's guidance assumptions for 2026, including pricing and transition assumptions for the adoption of pay-as-you go reimbursement in the United States and the initiation of international direct op...

View stock analysis, news, and events for Tandem Diabetes Care, Inc.